Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Preferred Stock Liabilities (2023)

CG Oncology filings provide 1 years of Preferred Stock Liabilities readings, the most recent being $22.0 million for Q4 2023.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $22.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $22.0 million, a N/A change, with the full-year FY2023 number at $22.0 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $22.0 million in Q4 2023 for CG Oncology, down from $47.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $47.3 million in Q1 2023 to a low of $22.0 million in Q2 2023.